Literature DB >> 17415794

Developmental effects of +/-3,4-methylenedioxymethamphetamine on spatial versus path integration learning: effects of dose distribution.

Charles V Vorhees1, Tori L Schaefer, Michael T Williams.   

Abstract

We previously demonstrated that postnatal day 11-20 +/-3,4-methylenedioxymethamphetamine (MDMA) exposure reduces locomotor activity and impairs path integration and spatial learning independent of the effects on activity. The effects were seen when the drug was administered twice per day, but the optimal dosing regimen is unknown. We tested whether the same total daily dose of MDMA administered in different patterns would equally affect later behavior. A split-litter design (15 litters) was used with one male/female pair per litter receiving one of four treatment regimens. All offspring received four injections per day on P11-20 as follows: 40 x 1 (40 mg/kg MDMA x 1 + saline x 3), 20 x 2 (20 mg/kg MDMA x 2 + saline x 2), 10 x 4 (10 mg/kg MDMA x 4), or Saline (saline x 4). Doses were spaced 2 h apart. Group 40 x 1 received MDMA as the first daily dose followed by three saline doses; group 20 x 2 received MDMA as the first and last dose and saline for the middle two doses; group 10 x 4 received MDMA for all four doses; and the saline group received saline for all four doses. Regardless of dose schedule, all groups treated with MDMA exhibited reduced locomotor activity. No MDMA effects were found on swimming ability in a straight channel. Modest MDMA effects were found on Barnes maze performance. The major findings were that the 40 x 1 and 20 x 2 MDMA groups showed impaired Cincinnati multiple T-water-maze learning and the 10 x 4 and 20 x 2 MDMA groups showed impaired Morris water maze learning. The results suggest that MDMA dose distribution has a long-term differential effect on different types of learning. Dose distribution warrants greater attention in the design of developmental drug studies along with the standard considerations of dose and age.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17415794      PMCID: PMC2888320          DOI: 10.1002/syn.20379

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  37 in total

1.  Congenital anomalies after prenatal ecstasy exposure.

Authors:  P R McElhatton; D N Bateman; C Evans; K R Pughe; S H Thomas
Journal:  Lancet       Date:  1999-10-23       Impact factor: 79.321

2.  Impaired recognition memory in rats after damage to the hippocampus.

Authors:  R E Clark; S M Zola; L R Squire
Journal:  J Neurosci       Date:  2000-12-01       Impact factor: 6.167

3.  3,4-methylenedioxymethamphetamine (ecstasy)-induced learning and memory impairments depend on the age of exposure during early development.

Authors:  H W Broening; L L Morford; S L Inman-Wood; M Fukumura; C V Vorhees
Journal:  J Neurosci       Date:  2001-05-01       Impact factor: 6.167

4.  Characteristics of pregnant women who use ecstasy (3, 4-methylenedioxymethamphetamine).

Authors:  E Ho; L Karimi-Tabesh; G Koren
Journal:  Neurotoxicol Teratol       Date:  2001 Nov-Dec       Impact factor: 3.763

5.  Functional consequences of perinatal exposure to 3,4-methylenedioxymethamphetamine in rat brain.

Authors:  Paul A T Kelly; Isobel M Ritchie; Linda Quate; Douglas E McBean; Henry J Olverman
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

6.  Translating developmental time across mammalian species.

Authors:  B Clancy; R B Darlington; B L Finlay
Journal:  Neuroscience       Date:  2001       Impact factor: 3.590

7.  Fetal exposure to (+/-)-methylenedioxymethamphetamine in utero enhances the development and metabolism of serotonergic neurons in three-dimensional reaggregate tissue culture.

Authors:  Lisa Won; Nancy Bubula; Alfred Heller
Journal:  Brain Res Dev Brain Res       Date:  2002-07-30

8.  Serotonergic neurotoxicity of MDMA (ecstasy) in the developing rat brain.

Authors:  Jerrold S Meyer; Syed F Ali
Journal:  Ann N Y Acad Sci       Date:  2002-06       Impact factor: 5.691

Review 9.  Critical periods of vulnerability for the developing nervous system: evidence from humans and animal models.

Authors:  D Rice; S Barone
Journal:  Environ Health Perspect       Date:  2000-06       Impact factor: 9.031

10.  Web-based method for translating neurodevelopment from laboratory species to humans.

Authors:  Barbara Clancy; Brandon Kersh; James Hyde; Richard B Darlington; K J S Anand; Barbara L Finlay
Journal:  Neuroinformatics       Date:  2007
View more
  17 in total

1.  Electroencephalographic and convulsive effects of binge doses of (+)-methamphetamine, 5-methoxydiisopropyltryptamine, and (±)-3,4-methylenedioxymethamphetamine in rats.

Authors:  Devon L Graham; Nicole R Herring; Tori L Schaefer; Katherine D Holland; Charles V Vorhees; Michael T Williams
Journal:  Open Neuropsychopharmacol J       Date:  2012

2.  Distinct periods of developmental sensitivity to the effects of 3,4-(±)-methylenedioxymethamphetamine (MDMA) on behaviour and monoamines in rats.

Authors:  Matthew R Skelton; Devon L Graham; Tori L Schaefer; Curtis E Grace; Amanda A Braun; Lindsey N Burns; Robyn M Amos-Kroohs; Michael T Williams; Charles V Vorhees
Journal:  Int J Neuropsychopharmacol       Date:  2011-06-28       Impact factor: 5.176

3.  Neurobehavioral outcomes of infants exposed to MDMA (Ecstasy) and other recreational drugs during pregnancy.

Authors:  Lynn T Singer; Derek G Moore; Sarah Fulton; Julia Goodwin; John J D Turner; Meeyoung O Min; Andrew C Parrott
Journal:  Neurotoxicol Teratol       Date:  2012-03-03       Impact factor: 3.763

4.  Short- and long-term effects of (+)-methamphetamine and (+/-)-3,4-methylenedioxymethamphetamine on monoamine and corticosterone levels in the neonatal rat following multiple days of treatment.

Authors:  Tori L Schaefer; Matthew R Skelton; Nicole R Herring; Gary A Gudelsky; Charles V Vorhees; Michael T Williams
Journal:  J Neurochem       Date:  2007-11-06       Impact factor: 5.372

5.  Mouse plasmacytoma-expressed transcript 1 knock out induced 5-HT disruption results in a lack of cognitive deficits and an anxiety phenotype complicated by hypoactivity and defensiveness.

Authors:  T L Schaefer; C V Vorhees; M T Williams
Journal:  Neuroscience       Date:  2009-09-25       Impact factor: 3.590

Review 6.  Developmental effects of 3,4-methylenedioxymethamphetamine: a review.

Authors:  Matthew R Skelton; Michael T Williams; Charles V Vorhees
Journal:  Behav Pharmacol       Date:  2008-03       Impact factor: 2.293

7.  (+/-)3,4-Methylenedioxymethamphetamine (MDMA) dose-dependently impairs spatial learning in the morris water maze after exposure of rats to different five-day intervals from birth to postnatal day twenty.

Authors:  Charles V Vorhees; Tori L Schaefer; Matthew R Skelton; Curtis E Grace; Nicole R Herring; Michael T Williams
Journal:  Dev Neurosci       Date:  2009-04-17       Impact factor: 2.984

Review 8.  Cincinnati water maze: A review of the development, methods, and evidence as a test of egocentric learning and memory.

Authors:  Charles V Vorhees; Michael T Williams
Journal:  Neurotoxicol Teratol       Date:  2016-08-18       Impact factor: 3.763

9.  Glucose and corticosterone changes in developing and adult rats following exposure to (+/-)-3,4-methylendioxymethamphetamine or 5-methoxydiisopropyltryptamine.

Authors:  Devon L Graham; Nicole R Herring; Tori L Schaefer; Charles V Vorhees; Michael T Williams
Journal:  Neurotoxicol Teratol       Date:  2009-09-06       Impact factor: 3.763

10.  Cognitive impairments from developmental exposure to serotonergic drugs: citalopram and MDMA.

Authors:  Tori L Schaefer; Curtis E Grace; Amanda A Braun; Robyn M Amos-Kroohs; Devon L Graham; Matthew R Skelton; Michael T Williams; Charles V Vorhees
Journal:  Int J Neuropsychopharmacol       Date:  2013-01-11       Impact factor: 5.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.